VERTICAL-GROUP-HOLDING
21.10.2020 09:02:50 CEST | Business Wire | Press release
BNP Paribas’ CEO and Chairman have been ordered to appear before a Maltese court, where they face questions about the French bank’s alleged involvement with a highly controversial deal in Malta, and about serious alleged ethical, legal and professional violations at the bank, Vertical Group Holding announces today.
Jean-Laurent Bonnafé and Jean Lemierre, two of France’s highest-profile executives, will be pressed to give evidence as witnesses in court concerning their roles in an alleged plot by BNP Paribas to discredit a financier of British-Israeli background who had criticized the bank over its admitted involvement in multiple criminal activities, including money-laundering for pariah regimes.
Jacob Agam, alongside Malta-based Vertical Group, the international private equity group he chairs, is bringing a civil lawsuit against both men and BNP itself for what he alleges was the bank’s deliberate and unlawful destruction of the business’s assets. BNP and the executives dispute the claim.
Agam alleges he was targeted by the bank after raising concerns publicly and privately about its role in a number of controversies. These included a 2014 criminal conviction imposed on BNP by the US Government for unlawfully processing transactions worth billions of dollars for sanctioned regimes linked to terrorism and genocide.
In an unusual development for a front-ranking French company, Bonnafé and Lemierre were summoned to give witness evidence at a hearing next month, after Vertical secured a court summons against them. Bailiffs served the summons on them at the €41bn bank’s Paris headquarters in September. It is one of the first times since the Global Financial Crisis that a major bank’s top executives, rather than lower-ranking officials, will be obliged to give public witness-box evidence in civil proceedings.
The legal action brought by Vertical and Agam makes pathfinding use of a 2012 European Union Directive, which enables a resident or company of one EU member state to use its home court to sue defendants elsewhere in the EU. Bonnafé and Lemierre have been informed by the court that they will be in contempt of court if they disobey the summons and fail to appear before the Honourable Joseph Zammit McKeon, the presiding judge, at the Courts of Justice Building in Valletta, Malta, on November 3.
The summons, which cannot be appealed, is the culmination of protracted efforts to get the BNP bosses to court, after previous summonses were not observed. The court has informed Bonnafé and Lemierre it may issue an arrest warrant for them if they do not attend.
Although the pair can choose whether or not to give evidence in relation to their status as defendants in the case, under civil court rules they are obliged to give evidence as witnesses in matters relating to the bank’s alleged role.
The November hearing’s principal purpose is to hear evidence about whether the Maltese court has jurisdiction over the case. BNP has previously argued it should not be heard in Malta, and has claimed it has no business there.
Bonnafé and Lemierre will be questioned closely on this claim, which appears to contrast with recent reports identifying BNP as part of a financing syndicate for Electrogas, a power station company dogged by extreme controversy in Malta. The company’s former director Yorgen Fenech has been charged with conspiracy to murder Daphne Caruana Galizia, the journalist assassinated in 2017, which he denies. There is no suggestion of any link between Caruana Galizia’s death and BNP.
A connection between BNP and Electrogas was first asserted in court testimony provided by Agam at an earlier hearing in February 2020. In a separate complaint, France’s National Financial Prosecutor’s Office has been asked to investigate BNP’s deal with Electrogas by the Daphne Caruana Galizia Foundation, an anti-corruption NGO named after the murdered reporter. She was killed after investigating business practices at Electrogas and elsewhere.
Bonnafé and Lemierre will also face calls to give evidence about their alleged personal involvement in decisions made within BNP that allegedly caused the unwarranted destruction of Agam’s and Vertical’s business interests. The defendants are accused of retaliating with a smear campaign against Agam and Vertical Group, in breach of defamation and banking laws.
Agam, who is of British-Israeli background with a Jewish heritage, and had been a longstanding client of BNP, claims the bank abruptly terminated his companies’ investment facilities, sought to seize his family’s properties, and defamed him in the media, with the knowledge of the CEO and Chairman. The bank’s legal representative also used antisemitic and derogatory language, calling Jews “parasites”, according to the lawsuit. Agam claims the bank’s leadership failed to take any action to investigate, mitigate or apologise for this and other alleged episodes, despite repeated requests to do so, and accuses them of presiding over anti-semitic practices.
Agam and Vertical claim the alleged campaign against his interests started after he raised concerns with BNP following a number of major public scandals involving the bank. In 2014, BNP pleaded guilty to two criminal charges and agreed to pay almost $9 billion to resolve accusations it violated US sanctions aimed at thwarting brutal regimes in Iran, Sudan and elsewhere. Separately, BNP reached an out-of-court settlement in New York in 2016 with a Jewish employee who claimed he was penalized for complaining about a training film that featured a frivolous portrayal of Hitler and Nazi imagery.
The bank and the other defendants reject the allegations brought in the lawsuit by Agam and Vertical. They deny the existence of a plot against the claimants and say the claims of antisemitism are conjectures by the claimants which are denied.
Jacob Agam said: “I hope these hearings will bring to an end the bank’s lengthy efforts to shield itself and its management from questions they will deservedly find very unpleasant and difficult. Dealing with BNP has been a far more unpleasant and difficult experience for me, my family and my business. My claim is that the bank’s actions against me were partly motivated by racial bigotry and antisemitism. This has been especially hard to live with given BNP’s admitted criminal and unethical behaviour in the recent past.
“BNP is, quite literally, a scandalous organisation. Bonnafé and Lemierre have presided over those scandals. So it is shocking they have never been held personally responsible for the bank’s misconduct - even when the bank settled a lawsuit over alleged antisemitism, or was fined billions of dollars for financial transactions that assisted terrorism and genocide.
“Neither the bank nor its leaders should be allowed to escape the consequences of this horrendous conduct. Now, at last, the corporate veil has been drawn back. For the first time, the CEO and Chairman will be put under the spotlight, required to explain BNP’s controversial involvement in Malta, and to justify its previous claim that it did no business there. Its business in Malta is nothing to be proud of, to judge from its partnership with Electrogas.
“I also want them to face searching questions about their alleged personal involvement in the destruction of my family assets.”
Dr Pio Valletta of Farrugia, Gatt & Falzon, Maltese attorney for Mr Agam and Vertical Holdings, added: “This is an important test-case regarding the applicability of European Union rules. It demonstrates that nobody can escape from their statutory duties, not even a mighty organisation like BNP and its management. The recent ruling of the Maltese Court reaffirms the fundamental principle that ‘be you ever so high, the law is above you’. Messrs Bonnafé and Lemierre may preside over the world’s eighth-largest bank. But they and the bank must still submit to a serious examination of their actions before the court.”
Hearings are scheduled to begin at 11am CET on November 3 before the Honourable Mr Justice Joseph Zammit McKeon on the second floor of the Courts of Justice Building, Valletta, Malta. The case is Vertical Group Holding and oth v BNP Paribas SA and oth, The case number is 218/2019 JZM.
Notes for editors
About the litigation
BNP Paribas, its Chairman Jean Lemierre, CEO Jean-Laurent Bonnafé and the bank’s legal representative Valérie Lafarge-Sarkozy are the subjects of a lawsuit filed on behalf of Jacob Agam and Vertical Group Holding Ltd (“Vertical Group”) in Malta on March 1, 2019. The bank and other defendants are accused of defamation and violation of banking laws, and of conducting a smear campaign that severely damaged the claimants’ business interests, professional reputation and credit standing. The bank’s alleged actions stemmed from a dispute between the parties, it is claimed, which arose after Agam persistently challenged the bank from 2014 over its admitted involvement in criminal acts, including US sanctions-busting and facilitating transactions with regimes involved in attacks on the State of Israel.
According to the lawsuit, the bank targeted Agam by abruptly terminating his companies’ investment facilities without justification and attempting to seize family properties. It is also alleged Lafarge-Sarkozy used anti-semitic language, referring to Jews as “ces gens-là” (“these people”, a highly derogatory phrase in the French language) and “parasites”. The bank’s CEO and Chairman, despite receiving many personal requests to intervene, failed to prevent the alleged destructive smear campaign against the claimants, according to the legal claim. It is also alleged that the CEO did not respond to a formal letter from members of Israel’s parliament, expressing concerns about the case.
The bank disputes all the allegations brought in the lawsuit by Agam and Vertical. It says the claims of antisemitism are conjectures by the claimants which are denied.
The legal claim states that the claimants have honoured all their financial obligations to the bank, and that the bank has acknowledged this.
About Vertical Group Holding and Jacob Agam
Vertical Group Holding is a private equity company, headquartered in Malta, that makes investments across a range of sectors and geographies, with an active involvement in the management and development of portfolio companies. Over nearly three decades, its investee companies have created and enjoyed equity valuations totalling more than €3.5bn. Its current portfolio includes companies in the US, Israel and across Europe, in software, healthcare, media, gaming, renewable energy, food, robotics and other industries.
Vertical is owned by Jacob Agam and was founded in 1991. After a career in the Israeli military and as a diplomat for Israel, Jacob Aram trained as a lawyer in New York, working for a Wall Street firm before founding Vertical in 1991.
Agam currently serves on the boards of several companies and is a significant philanthropist, having supported charities fighting poverty and illiteracy in Africa, medical research, and the archaeological preservation of early Jerusalem. He also helped fund the Peres Center for Peace NGO in Tel Aviv.
Further information is available at www.verticalcapital.biz.
Earlier litigation involving BNP Paribas
Headquartered in Paris, and with operations in more than 70 countries and approximately 200,000 employees globally, BNP Paribas is one of France’s leading corporate institutions and the eighth-largest banking group in the world by market value. With a history stretching back to the 1840s, BNP Paribas is a constituent of the CAC 40 index, and has a current market capitalization of €41 billion. The group is active in retail banking, corporate lending, investment banking and asset management across five continents.
In 2014, BNP Paribas accepted a record-breaking $9bn fine from the US Department of Justice after pleading guilty to flouting America’s sanctions regime by facilitating transactions for regimes that support terrorism. The bank admitted that between at least 2004 through 2012, it knowingly and wilfully moved over $8.8bn through the American financial system on behalf of Sudanese, Iranian and Cuban sanctioned entities, in violation of US economic sanctions. BNP Paribas also admitted falsifying business records, and was roundly condemned by US prosecutors. The bank is reportedly also facing legal action brought in France on behalf of victims of the Darfur genocide, alleging BNP Paribas is complicit in crimes against humanity.
The US Government’s announcement of the fine and criminal conviction against BNP Paribas can be viewed at https://www.justice.gov/opa/pr/bnp-paribas-agrees-plead-guilty-and-pay-89-billion-illegally-processing-financial .
In 2016, the bank reached an out of court settlement in New York with Jean-Marc Orlando, an Orthodox Jew who had worked as a managing director for BNP Paribas North America. Orlando claimed the bank fired him for his religious beliefs after he complained about Nazi imagery in a training video. The video, created by BNP employees, was a parody of the 2004 film Downfall, which depicted the final days of Adolf Hitler’s Nazi regime in Germany, he claimed. The film portrayed the head of BNP competitor Deutsche Bank as Hitler, the lawsuit said. BNP did not admit liability as part of the settlement.
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
